Prospective evaluation of parenteral magnesium sulfate in the treatment of patients with reentrant AV supraventricular tachycardia

Philip T. Sager, Josef Widerhorn, Ronald Carl Petersen, Cheryl Leon, Elisabeth Ryzen, Robert Rude, Shahbudin H. Rahimtoola, Anil K. Bhandari

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

This study prospectively assessed the electrophysiologic effects of parenteral magnesium sulfate administration on paroxysmal atrioventricular (AV) reentrant supraventricular tachycardia and the efficacy of magnesium to terminate these arrhythmias. Eleven normomagnesemic patients, seven with orthodromic reentrant supraventricular tachycardia that used an accessory AV pathway, and four with typical AV nodal reentry were examined. All patients had a history of sustained supraventricular tachycardia requiring pharmacologic therapy or electrical cardioversion for termination of tachycardia. After baseline electrophysiologic study, including documentation of sustained supraventricular tachycardia that was reproducibly induced, parenteral magnesium sulfate (a bolus of 0.3 mEq/kg of elemental magnesium infused over a 10-minute period followed by a maintenance infusion of 0.2 mEq/kg/hr) was administered during sustained supraventricular tachycardia. The serum magnesium concentration increased from (mean±standard deviation) 1.9±0.2 mg/dl to 4.0±0.6 mg/dl (p=0.0001). Except for flushing and mild diaphoresis during infusion of the magnesium sulfate bolus, and dry heaves in one patient, there were no untoward effects or significant changes in systolic blood pressure. During administration of magnesium, the tachycardia cycle length increased from 319±39 msec to 348±43 msec (p=0.0001). Slowing of the tachycardia occurred predominantly in the antegrade limb of the circuit at the level of the AV node with the AH interval increasing from 171±66 msec to 197±68 msec (p=0.0001), whereas there was no significant change in the HV interval (43±3 msec to 43±4 msec, p=NS) or the VA interval (106±43 msec to 110±47 msec, p=NS) during tachycardia. In two patients the tachycardia terminated spontaneously. However, termination of supraventricular tachycardia in these patients was the result of three- and four-beat runs of spontaneous nonsustained ventricular tachycardia. Administration of magnesium did not suppress the inducibility of supraventricular tachycardia in any patient or significantly influence the effective refractory periods of the right atrium, AV node, accessory pathway, or right ventricle. Thus in normomagnesemic patients with reentrant paroxysmal supraventricular tachycardia, parenterally administered magnesium sulfate increases the tachycardia cycle length by slowing the antegrade limb of the reentrant circuit at the level of the AV node. Although it slows the tachycardia, magnesium sulfate is only rarely effective in terminating supraventricular tachycardia.

Original languageEnglish (US)
Pages (from-to)308-316
Number of pages9
JournalAmerican Heart Journal
Volume119
Issue number2 PART 1
DOIs
StatePublished - 1990

Fingerprint

Magnesium Sulfate
Supraventricular Tachycardia
Tachycardia
Magnesium
Atrioventricular Node
Therapeutics
Extremities
Accessory Atrioventricular Bundle
Blood Pressure
Paroxysmal Tachycardia
Electric Countershock
Ventricular Tachycardia
Heart Atria
Documentation
Heart Ventricles
Cardiac Arrhythmias
Maintenance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prospective evaluation of parenteral magnesium sulfate in the treatment of patients with reentrant AV supraventricular tachycardia. / Sager, Philip T.; Widerhorn, Josef; Petersen, Ronald Carl; Leon, Cheryl; Ryzen, Elisabeth; Rude, Robert; Rahimtoola, Shahbudin H.; Bhandari, Anil K.

In: American Heart Journal, Vol. 119, No. 2 PART 1, 1990, p. 308-316.

Research output: Contribution to journalArticle

Sager, Philip T. ; Widerhorn, Josef ; Petersen, Ronald Carl ; Leon, Cheryl ; Ryzen, Elisabeth ; Rude, Robert ; Rahimtoola, Shahbudin H. ; Bhandari, Anil K. / Prospective evaluation of parenteral magnesium sulfate in the treatment of patients with reentrant AV supraventricular tachycardia. In: American Heart Journal. 1990 ; Vol. 119, No. 2 PART 1. pp. 308-316.
@article{e98071419732431192d284f44deee89a,
title = "Prospective evaluation of parenteral magnesium sulfate in the treatment of patients with reentrant AV supraventricular tachycardia",
abstract = "This study prospectively assessed the electrophysiologic effects of parenteral magnesium sulfate administration on paroxysmal atrioventricular (AV) reentrant supraventricular tachycardia and the efficacy of magnesium to terminate these arrhythmias. Eleven normomagnesemic patients, seven with orthodromic reentrant supraventricular tachycardia that used an accessory AV pathway, and four with typical AV nodal reentry were examined. All patients had a history of sustained supraventricular tachycardia requiring pharmacologic therapy or electrical cardioversion for termination of tachycardia. After baseline electrophysiologic study, including documentation of sustained supraventricular tachycardia that was reproducibly induced, parenteral magnesium sulfate (a bolus of 0.3 mEq/kg of elemental magnesium infused over a 10-minute period followed by a maintenance infusion of 0.2 mEq/kg/hr) was administered during sustained supraventricular tachycardia. The serum magnesium concentration increased from (mean±standard deviation) 1.9±0.2 mg/dl to 4.0±0.6 mg/dl (p=0.0001). Except for flushing and mild diaphoresis during infusion of the magnesium sulfate bolus, and dry heaves in one patient, there were no untoward effects or significant changes in systolic blood pressure. During administration of magnesium, the tachycardia cycle length increased from 319±39 msec to 348±43 msec (p=0.0001). Slowing of the tachycardia occurred predominantly in the antegrade limb of the circuit at the level of the AV node with the AH interval increasing from 171±66 msec to 197±68 msec (p=0.0001), whereas there was no significant change in the HV interval (43±3 msec to 43±4 msec, p=NS) or the VA interval (106±43 msec to 110±47 msec, p=NS) during tachycardia. In two patients the tachycardia terminated spontaneously. However, termination of supraventricular tachycardia in these patients was the result of three- and four-beat runs of spontaneous nonsustained ventricular tachycardia. Administration of magnesium did not suppress the inducibility of supraventricular tachycardia in any patient or significantly influence the effective refractory periods of the right atrium, AV node, accessory pathway, or right ventricle. Thus in normomagnesemic patients with reentrant paroxysmal supraventricular tachycardia, parenterally administered magnesium sulfate increases the tachycardia cycle length by slowing the antegrade limb of the reentrant circuit at the level of the AV node. Although it slows the tachycardia, magnesium sulfate is only rarely effective in terminating supraventricular tachycardia.",
author = "Sager, {Philip T.} and Josef Widerhorn and Petersen, {Ronald Carl} and Cheryl Leon and Elisabeth Ryzen and Robert Rude and Rahimtoola, {Shahbudin H.} and Bhandari, {Anil K.}",
year = "1990",
doi = "10.1016/S0002-8703(05)80021-3",
language = "English (US)",
volume = "119",
pages = "308--316",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "2 PART 1",

}

TY - JOUR

T1 - Prospective evaluation of parenteral magnesium sulfate in the treatment of patients with reentrant AV supraventricular tachycardia

AU - Sager, Philip T.

AU - Widerhorn, Josef

AU - Petersen, Ronald Carl

AU - Leon, Cheryl

AU - Ryzen, Elisabeth

AU - Rude, Robert

AU - Rahimtoola, Shahbudin H.

AU - Bhandari, Anil K.

PY - 1990

Y1 - 1990

N2 - This study prospectively assessed the electrophysiologic effects of parenteral magnesium sulfate administration on paroxysmal atrioventricular (AV) reentrant supraventricular tachycardia and the efficacy of magnesium to terminate these arrhythmias. Eleven normomagnesemic patients, seven with orthodromic reentrant supraventricular tachycardia that used an accessory AV pathway, and four with typical AV nodal reentry were examined. All patients had a history of sustained supraventricular tachycardia requiring pharmacologic therapy or electrical cardioversion for termination of tachycardia. After baseline electrophysiologic study, including documentation of sustained supraventricular tachycardia that was reproducibly induced, parenteral magnesium sulfate (a bolus of 0.3 mEq/kg of elemental magnesium infused over a 10-minute period followed by a maintenance infusion of 0.2 mEq/kg/hr) was administered during sustained supraventricular tachycardia. The serum magnesium concentration increased from (mean±standard deviation) 1.9±0.2 mg/dl to 4.0±0.6 mg/dl (p=0.0001). Except for flushing and mild diaphoresis during infusion of the magnesium sulfate bolus, and dry heaves in one patient, there were no untoward effects or significant changes in systolic blood pressure. During administration of magnesium, the tachycardia cycle length increased from 319±39 msec to 348±43 msec (p=0.0001). Slowing of the tachycardia occurred predominantly in the antegrade limb of the circuit at the level of the AV node with the AH interval increasing from 171±66 msec to 197±68 msec (p=0.0001), whereas there was no significant change in the HV interval (43±3 msec to 43±4 msec, p=NS) or the VA interval (106±43 msec to 110±47 msec, p=NS) during tachycardia. In two patients the tachycardia terminated spontaneously. However, termination of supraventricular tachycardia in these patients was the result of three- and four-beat runs of spontaneous nonsustained ventricular tachycardia. Administration of magnesium did not suppress the inducibility of supraventricular tachycardia in any patient or significantly influence the effective refractory periods of the right atrium, AV node, accessory pathway, or right ventricle. Thus in normomagnesemic patients with reentrant paroxysmal supraventricular tachycardia, parenterally administered magnesium sulfate increases the tachycardia cycle length by slowing the antegrade limb of the reentrant circuit at the level of the AV node. Although it slows the tachycardia, magnesium sulfate is only rarely effective in terminating supraventricular tachycardia.

AB - This study prospectively assessed the electrophysiologic effects of parenteral magnesium sulfate administration on paroxysmal atrioventricular (AV) reentrant supraventricular tachycardia and the efficacy of magnesium to terminate these arrhythmias. Eleven normomagnesemic patients, seven with orthodromic reentrant supraventricular tachycardia that used an accessory AV pathway, and four with typical AV nodal reentry were examined. All patients had a history of sustained supraventricular tachycardia requiring pharmacologic therapy or electrical cardioversion for termination of tachycardia. After baseline electrophysiologic study, including documentation of sustained supraventricular tachycardia that was reproducibly induced, parenteral magnesium sulfate (a bolus of 0.3 mEq/kg of elemental magnesium infused over a 10-minute period followed by a maintenance infusion of 0.2 mEq/kg/hr) was administered during sustained supraventricular tachycardia. The serum magnesium concentration increased from (mean±standard deviation) 1.9±0.2 mg/dl to 4.0±0.6 mg/dl (p=0.0001). Except for flushing and mild diaphoresis during infusion of the magnesium sulfate bolus, and dry heaves in one patient, there were no untoward effects or significant changes in systolic blood pressure. During administration of magnesium, the tachycardia cycle length increased from 319±39 msec to 348±43 msec (p=0.0001). Slowing of the tachycardia occurred predominantly in the antegrade limb of the circuit at the level of the AV node with the AH interval increasing from 171±66 msec to 197±68 msec (p=0.0001), whereas there was no significant change in the HV interval (43±3 msec to 43±4 msec, p=NS) or the VA interval (106±43 msec to 110±47 msec, p=NS) during tachycardia. In two patients the tachycardia terminated spontaneously. However, termination of supraventricular tachycardia in these patients was the result of three- and four-beat runs of spontaneous nonsustained ventricular tachycardia. Administration of magnesium did not suppress the inducibility of supraventricular tachycardia in any patient or significantly influence the effective refractory periods of the right atrium, AV node, accessory pathway, or right ventricle. Thus in normomagnesemic patients with reentrant paroxysmal supraventricular tachycardia, parenterally administered magnesium sulfate increases the tachycardia cycle length by slowing the antegrade limb of the reentrant circuit at the level of the AV node. Although it slows the tachycardia, magnesium sulfate is only rarely effective in terminating supraventricular tachycardia.

UR - http://www.scopus.com/inward/record.url?scp=0025014259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025014259&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(05)80021-3

DO - 10.1016/S0002-8703(05)80021-3

M3 - Article

C2 - 2301220

AN - SCOPUS:0025014259

VL - 119

SP - 308

EP - 316

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 2 PART 1

ER -